BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 15780528)

  • 1. Effects of transdermal estrogen replacement therapy on plasma levels of nitric oxide and plasma lipids in postmenopausal women.
    Balci H; Altunyurt S; Acar B; Fadiloglu M; Kirkali G; Onvural B
    Maturitas; 2005 Apr; 50(4):289-93. PubMed ID: 15780528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
    Vrablik M; Fait T; Kovar J; Poledne R; Ceska R
    Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
    Hemelaar M; van der Mooren MJ; Mijatovic V; Bouman AA; Schijf CP; Kroeks MV; Franke HR; Kenemans P
    Menopause; 2003; 10(6):550-8. PubMed ID: 14627865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
    Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
    J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA; Farias ML; Andrade AT
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
    Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
    Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: a randomized controlled trial.
    Meschia M; Bruschi F; Soma M; Amicarelli F; Paoletti R; Crosignani P
    Menopause; 1998; 5(3):157-62. PubMed ID: 9774761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
    Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
    Gynecol Endocrinol; 2002 Apr; 16(2):155-62. PubMed ID: 12012627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.
    Walsh BW; Schiff I; Rosner B; Greenberg L; Ravnikar V; Sacks FM
    N Engl J Med; 1991 Oct; 325(17):1196-204. PubMed ID: 1922206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
    Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
    Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.
    Hemelaar M; Kenemans P; de Bie L; van de Weijer PH; van der Mooren MJ
    Fertil Steril; 2006 Apr; 85(4):979-88. PubMed ID: 16580384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
    Brynhildsen J; Hammar M
    Maturitas; 2005 Apr; 50(4):344-52. PubMed ID: 15780536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial.
    Falkeborn M; Lithell H; Persson I; Vessby B; Naessén T
    Climacteric; 2002 Sep; 5(3):240-8. PubMed ID: 12419082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins.
    Marsh MS; Crook D; Whitcroft SI; Worthington M; Whitehead MI; Stevenson JC
    Obstet Gynecol; 1994 Jan; 83(1):19-23. PubMed ID: 8272301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
    Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
    Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.